Skip to main content

Table 5 Continuous sedative and analgesic infusions

From: Effect of an analgo-sedation protocol for neurointensive patients: a two-phase interventional non-randomized pilot study

 

Observational period

(n = 106, days = 553)

Intervention period

(n = 109, days = 556)

P Value

Propofol days (% of total days)

307 (56%)

283 (51%)

.006*

Mean dose/day (mg) ± SD

2,592 ± 1,623

2,074 ± 1,308

< .001*

Range (mg)

550 to 7,910

510 to 7,070

 

Midazolam days (% of total days)

49 (9%)

80 (14%)

.078

Mean dose/day (mg) ± SD

238 ± 152

157 ± 122

.001*

Range (mg)

3 to 485

0 to 425

 

Fentanyl days (% of total days)

137 (25%)

114 (21%)

.171

Mean dose/day (mcg) ± SD

2,303 ± 1,606

4,919 ± 3,588

< .001*

Range (mcg)

80 to 8,000

100 to 16,000

 

Remifentanil days (% of total days)

297 (54%)

420 (76%)

.281

Mean dose/day (mcg) ± SD

6,888 ± 5,373

8,233 ± 6,384

.003*

Range (mcg)

1,000 to 18,000

1,000 to 19,000

 

Morphine days (% of total days)

41 (7%)

7 (1%)

.009*

Mean dose/day (mg) ± SD

16 ± 9

10 ± 0

.077

Range (mg)

7 to 40

10 to 10

 

Oxycodone days (% of total days)

67 (12%)

74 (13%)

.199

Mean dose/day (mg) ± SD

25 ± 22

20 ± 14

.079

Range (mg)

5 to 100

3 to 69

 
  1. Number of days (t-test), medication dose (Mann-Whitney), and * P value ≤ .05 significant. Range was calculated within limits of adequate sedation.